An Investigation of Levetiracetam in Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 28, 2018

Primary Completion Date

March 21, 2022

Study Completion Date

March 21, 2022

Conditions
Alzheimer DiseaseEpilepsy
Interventions
DRUG

Levetiracetam

To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks

DRUG

Placebo Oral Tablet

To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks

Trial Locations (1)

OX39DU

Nuffield Department of Clinical Neuroscience, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oxford University Hospitals NHS Trust

OTHER

collaborator

Oxford Health NHS Foundation Trust

OTHER_GOV

collaborator

Northumberland, Tyne and Wear NHS Foundation Trust

OTHER

collaborator

UCB Pharma

INDUSTRY

lead

University of Oxford

OTHER